Page last updated: 2024-12-08

aclarubicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID451415
CHEMBL ID502620
CHEBI ID77980
CHEBI ID74619
SCHEMBL ID4532
MeSH IDM0023487

Synonyms (67)

Synonym
aclacinon
aclacin
methyl (1r,2r,4s)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-o-{2,6-dideoxy-4-o-[(2r,6s)-6-methyl-5-oxotetrahydro-2h-pyran-2-yl]-alpha-l-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-
D02756
aclarubicin (usan/inn)
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)
1-naphthacenecarboxylic acid,(2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)
antibiotic ma 144a
einecs 260-824-3
ccris 2262
aclarubicino [inn-spanish]
aclarubicinum [inn-latin]
methyl (1r,2r,4s)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r,6s)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-1-naphthac
aclarubicine [inn-french]
antibiotic ma 144a1
aclacur
SPECTRUM_000467
nsc-208734
ma 144-a1
SPECTRUM5_001041
jaclacin
aclacinomycin a
methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-4-(dimethylamino)-5-[(2s,4s,5s,6s)-4-hydroxy-6-methyl-5-[(2r,6s)-6-methyl-5-oxo-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-6-methyl-tetrahydropyran-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetra
2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-o-[2,6-dideoxy-4-o-[(2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl]-.alpha.-l-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-l-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxa
aclarubicin
KBIO2_003515
KBIOSS_000947
KBIOGR_001156
KBIO2_000947
KBIO2_006083
SPECTRUM2_001934
SPBIO_001967
SPECTRUM4_000768
HMS2089B13
methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-4-(dimethylamino)-5-[(2s,4s,5s,6s)-4-hydroxy-6-methyl-5-[(2r,6s)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
chebi:77980 ,
CHEMBL502620
C18638
CCG-39864
bdbm50368351
unii-74kxf8i502
aclarubicinum
aclarubicine
aclarubicin [usan:inn:ban]
74kxf8i502 ,
aclarubicino
aclarubicina
CHEBI:74619
aclacinomycin a [mi]
aclarubicin [usan]
aclarubicin [mart.]
aclarubicin [jan]
aclarubicin [who-dd]
aclarubicin [inn]
AW8655
SCHEMBL4532
AB00052311-02
USZYSDMBJDPRIF-SVEJIMAYSA-N
aclacinomycin a1
DTXSID1022554
aclarubicins
DB11617
Q4674302
1-naphthacenecarboxylic acid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-o-[2,6-dideoxy-4-o-[(2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl]-a-l-lyxo-hexopyranosyl]-3-(dimethylamino)-a-l-lyxo-hexopyranosyl]oxy]-, me
HY-N2306
CS-0020062
aclarunbicin

Research Excerpts

Overview

Aclarubicin (Aclaplastin) is a new cytostatic agent, from the group of anthracyclines. It has fewer side effects and clearly diminished cardiotoxicity.

ExcerptReferenceRelevance
"Aclarubicin is an anthracycline antibiotic that differs from doxorubicin in its structure, mechanism of action, and preclinical toxicity profile, especially its reduced cardiotoxicity. "( An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs.
Cody, RL; Natale, RB; Simon, MS; Wheeler, RH, 1993
)
2.01
"Aclarubicin (Aclaplastin) is a new cytostatic agent, from the group of anthracyclines, with fewer side effects and clearly diminished cardiotoxicity."( [Metastatic thyroid cancer: sudden death following aclarubicin therapy].
Beham, A; Eber, B; Eber, O; Klima, G; Költringer, P; Langsteger, W; Lind, P, 1989
)
1.25
"Aclarubicin is a new anthracycline antibiotic that produces substantially less cardiotoxicity in animals that does doxorubicin. "( Phase II study of aclarubicin in acute myeloblastic leukemia.
Bove, LG; Boyd, MA; Case, DC; Ervin, TJ; Paul, SD; Sonneborn, HL, 1987
)
2.05

Effects

ExcerptReferenceRelevance
"Aclarubicin (ACR) has a selective inhibitory effect on the synthesis of RNA in the cells. "( [Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
Egorenko, GG; Egorov, LV; Ivanitskaia, LP; Rudneva, NA; Terent'eva, TG, 1985
)
1.95
"Aclarubicin (ACR) has a selective inhibitory effect on the synthesis of RNA in the cells. "( [Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
Egorenko, GG; Egorov, LV; Ivanitskaia, LP; Rudneva, NA; Terent'eva, TG, 1985
)
1.95

Actions

ExcerptReferenceRelevance
"Aclarubicin can produce a significant response rate in previously treated patients with acute myeloblastic leukemia and should be considered for study in initial therapy."( Phase II study of aclarubicin in acute myeloblastic leukemia.
Bove, LG; Boyd, MA; Case, DC; Ervin, TJ; Paul, SD; Sonneborn, HL, 1987
)
1.33

Treatment

ExcerptReferenceRelevance
"Aclarubicin pretreatment attenuated phorbol 12, 13-dibutyrate (1 microM)-induced contraction both in the presence and absence of calcium in the medium."( Mechanisms in inhibitory action of aclarubicin on contractility of rat aorta.
Hatake, K; Masui, H; Sakamoto, K; Wakabayashi, I, 1995
)
1.29

Toxicity

Aclacinomycin A or aclarubicin is an anthracycline that, by contrast with daunomycin, lacks carcinogenicity and is less toxic to the retina. The duration of the toxic effects of ACR-CH was prolonged compared with that of the aClarubICin aqueous solution.

ExcerptReferenceRelevance
" The duration of the toxic effects of ACR-CH was prolonged compared with that of the aclarubicin aqueous solution."( A new dosage form comprising a suspension of activated carbon particles adsorbing aclarubicin: toxicity in mice.
Hagiwara, A; Ito, M; Iwamoto, A; Matsumoto, S; Muranishi, S; Sasabe, T; Takahashi, T; Yoneyama, C, 1991
)
0.73
" The LD50 values were 29 approximately 39 mg/kg (i."( [Acute toxicity of aclacinomycin A in mice, rats and dogs (author's transl)].
Hirano, S; Hori, S; Iguchi, H; Ohmori, K; Sato, H; Shirai, M, 1980
)
0.26
"Anthracycline antibiotics are principal agents in the treatment of acute non-lymphocytic leukemia, although the usefulness are limited by their adverse side effects, especially by the cardiotoxicity."( [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
Hamami, T; Haruyama, H; Ijichi, H; Isemura, T; Katsume, H; Nakagawa, M; Nakanishi, S; Nisio, A; Shimazaki, C, 1982
)
0.26
"Aclacinomycin A or aclarubicin is an anthracycline that, by contrast with daunomycin, lacks carcinogenicity and is less toxic to the retina."( Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro.
Loeffler, KU; Schmidt, JF, 1996
)
0.62
"HAA regimen may be an efficacious and safe regimen with a good toleration in the induction therapy for newly diagnosed AML, and a high CR rate could be achieved with only one or two courses."( [The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia].
Huang, J; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, JJ; Qian, WB; Song, YP; Tong, HY; Tong, Y; Xu, WL, 2011
)
0.37
" Thus, CAG represents a highly effective and safe salvage regimen for patients with AML who are refractory to the first induction chemotherapy."( Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Qin, YZ; Zhang, XH; Zhu, HH, 2013
)
0.77
" Cardiotoxicity is the most severe side effect of anthracycline administration."( [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Nesterov, VV; Shkolnik, EL; Shkolnik, LD; Varlan, GV; Vasyuk, YA, 2016
)
0.43
" Our preliminary results indicated that CAGLP was feasible, safe and effective as a salvage reinduction chemotherapy for primary refractory and relapsed ALL patients."( Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
Fang, B; Fu, Y; Liu, X; Song, Y; Wei, X; Yu, F; Zhang, Y; Zhou, H; Zhou, J; Zhou, K, 2017
)
0.7
" In terms of adverse reactions, there was no statistically significant difference in the rates of myelosuppression, pulmonary infection, gastrointestinal reactions, and bleeding events between the 2 groups (P>0."( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Cao, YP; Li, JG; Zhang, JL, 2019
)
0.75
" As compared with control group, there was no significant difference in adverse events."( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Cao, YP; Li, JG; Zhang, JL, 2019
)
0.75

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies were carried out in 7 patients."( Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin).
Archer, S; DeAngelis, C; Farrell, S; Hanna, S; Kerr, IG; McKee, J, 1987
)
0.5
" The pharmacokinetic profile of aclacinomycin-A in plasma and urine was studied in 3 patients given 65 mg/m2 using a high performance liquid chromatography assay."( Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.
Baker, LH; Franco, LA; Karanes, C; Samson, MK; Smith, LB; Young, JD, 1983
)
0.27
"We investigated the pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after intravenous (i."( HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs.
Ahan, KB; Chung, YB; Kang, MH; Kim, TY; Kwon, OS; Lee, HS; Moon, DC; Ryu, JS; Song, S; Yoo, BI, 2005
)
0.33
" To analyze ID-6105 levels in biological samples, we used an HPLC-based method which was validated in a pharmacokinetic study by suitable criteria."( Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats.
Ahan, KB; Chung, YB; Hong, YS; Kang, MH; Kim, TY; Kwon, OS; Lee, HS; Lee, JJ; Moon, DC; Ryu, JS; Song, S; Yoo, BI, 2005
)
0.33

Compound-Compound Interactions

The aim of this study was to evaluate the efficacy and toxicity of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF) protocol in elderly patients with acute myeloid leukemia.

ExcerptReferenceRelevance
"Sixty-six consecutive patients with unresectable hepatocellular carcinoma (HCC) were treated with transcatheter arterial chemoembolization (TACE) using aclarubicin microspheres (ACRms) in combination with cisplatin suspended in iodized oil (Lipiodol, Laboratoire Guerbert, Paris, France) (CSL)."( A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil.
Beppu, T; Fukushima, S; Ichihara, T; Ikei, S; Katafuchi, S; Mori, K; Nakano, M; Ohara, C; Yamaguchi, Y; Yamanaka, T, 1991
)
0.7
" When a case of such was found inoperable, she was subjected to radiotherapy combined with aclarubicin and neocarzinostatin."( [Radiotherapy combined with aclarubicin and neocarzinostatin in cancer of the gallbladder].
Funaki, K; Mishina, H; Mori, T; Okuyama, S, 1991
)
0.8
" Low ACM-A-concentrations combined with low X-ray doses showed on both cell lines supraadditive effects."( [The effect of adriamycin derivatives in combination with x-rays on MeWo and Be11 cells].
Krüger, M; Streffer, C; van Beuningen, D, 1990
)
0.28
"Fourteen patients with recurrent gynecological adenocarcinomas (nine with endometrial cancer and six with ovarian cancer) were treated with cisplatin given by 14-day continuous infusion at a daily dose of 10 mg/m2 in combination with aclarubicin (ACR) at a dose of 20 mg/body on alternate days during each 14-day course."( New cisplatin schedule in combination with aclarubicin (ACR) with high response rate in recurrent gynecological adenocarcinomas.
Chen, JT; Hasumi, K; Hirai, Y; Masubuchi, K; Shimizu, Y, 1990
)
0.72
"A new immunotherapy for hepatocellular carcinoma (HCC) using Freund's adjuvant and recombinant interleukin-2 (IL-2) combined with conventional transarterial chemoembolization therapy was performed."( Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma.
Higashi, T; Ikeda, N; Ito, T; Nouso, K; Ohsawa, T; Okamoto, T; Sue, K; Tsuji, T; Ukida, M; Watanabe, A, 1989
)
0.28
"Intrapleural treatment with aclacinomycin combined with closed tube thoracostomy was used in 7 patients with malignant pleural effusion."( [Efficacy of intrapleural treatment with aclacinomycin combined with closed tube thoracostomy for malignant pleural effusion].
Fujii, M; Fujita, Y; Ishimitsu, T; Okabe, K; Toki, H, 1984
)
0.27
"We treated breast cancer patients with Ps node involvement using an extended surgery (Ps+Sc, n = 17, group A) combined with targeting chemotherapy and compared the survival rate by this method with that by the dissection of the Ps node alone (n = 23, group B) to assess the prognosis of advanced breast cancer by extended surgery."( [Evaluation of parasternal (Ps) and supraclavicular (Sc) node dissection combined with targeting chemotherapy (activated carbon particle adsorbing aclarubicin) in breast cancer with Ps node involvement--usefulness of extended surgery for improvement of pr
Asaga, T; Masuzuma, C; Yoshida, A, 1994
)
0.49
"One hundred twelve patients with geriatric acute myeloid leukemia (AML), refractory or relapsed AML, or myelodysplastic syndrome and refractory anemia with excess of blasts in transformation (MDS-RAEBt) were entered into this study to receive CAG (aclarubicin and low-dose cytosine arabinoside [Ara-C]in combination with granulocyte colony-stimulating factor [G-CSF]) with the objective of evaluating the efficacy and tolerance of this regimen."( Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patien
Chen, FY; Hou, M; Jin, J; Li, JM; Liang, H; Qiu, XF; Qiu, ZC; Shen, Y; Shen, ZX; Song, EY; Song, YP; Wu, DP, 2005
)
1.95
"The aim of this study was to evaluate the efficacy and toxicity of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF) protocol in elderly patients with acute myeloid leukemia (AML)."( Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
Jiang, YQ; Li, JY; Lu, H; Qian, SX; Shen, YF; Tian, T; Wu, HX; Xu, W; Zhang, SJ, 2007
)
0.84
"To evaluate the efficacy and toxicity of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF) protocol for patients with relapsed acute myeloid leukemia (AML)."( [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, SJ; Zhu, BG, 2009
)
0.89
"We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia."( Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
Asou, N; Eto, K; Horikawa, K; Kugimiya, MH; Mitsuya, H; Nishimura, S; Shimomura, T; Suzushima, H; Tsuda, H; Wada, N; Yamasaki, H, 2010
)
0.92
"To evaluate the curative effect and adverse effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome."( [Curative effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome].
Chen, S; He, Y; Zhu, Y, 2010
)
0.36
" The CAG regimen [low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF)] has been used to treat relapsed and refractory AML patients, and showed good therapeutic efficacy."( Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Jin, Z; Lin, G; Liu, L; Ma, A; Si, Y; Sun, Y; Wang, L; Wu, D; Zhang, X; Zhang, Y; Zhao, G, 2014
)
0.98
"This study was aimed to investigate the clinical characteristics of relapsed-refractory acute myeloid leukemia (AML) with AML1-ETO⁺, and its therapeutic efficacy and side effects when decitabine combined with modified CAG regimen was used."( [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2014
)
0.4
"This study was purposed to compare the clinical efficacy and adverse reactions of low-dose decitabine combined with CAG regimen (aclarubicin, Ara-C, and G-CSF) and CAG regimen alone in intermediate to high-risk myelodysplastic syndromes (MDS), and evaluate the validity and efficacy of the former regimen as new treatment method of intermediate to high-risk myelodysplastic syndromes."( [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Cui, GX; Wu, WZ; Zhang, YP, 2014
)
0.61
"Treating MDS/AML with decitabine alone, in combination with half or one course CAG regimen produced high efficacy."( [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D, 2014
)
0.4
"This study was to investigate the therapeutic effectiveness and side effect of decitabine combined with modified CAG regimen for relapse or refractory patients with acute myeloid leukemia."( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015
)
0.42
"After treatment by using decitabine combined with modified CAG regimen, 7 patients achived complete remission, 1 patient achived partial remission, 2 patient did not achieve remission, the overall remission rate was 80% (8/10), the median time of white blood cell count recovery was 18."( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015
)
0.42
"The treatment of decitabine combined with modified CAG regimen for relapsed and refractory AML shows high response rate, low side effects, so it worthy to further clinical study."( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015
)
0.42
" In this study, we aimed to investigate the synergistic cytotoxic effect of low-dose arsenic trioxide (As2O3) combined with aclacinomycin A (ACM) on the human AML cell lines KG-1a and HL-60, and to clarify the underlying mechanism."( Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R, 2015
)
0.42
"All patients in this study were treated with decitabine of 15 mg/m2 for 5 days and G-CSF for priming, in combination with cytarabine of 10-mg/m2 q12h for 7 days and aclarubicin of 10 mg/day for 4 days (D-CAG)."( Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y, 2015
)
0.84
"To investigate the therapeutic efficacy and side effects of treating patients with myelodysplastic syndrome-RAEB (MDS-RAEB) and with refractory acute myeloid leukemia (AML) by using decitabine combined with CAG regimen."( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015
)
0.42
" All the patients received decitabine combined with CAG regimen consisting of decitabine 20 mg/(m(2) · d), d 1-5; aclarubicin 10 mg/d, d 6-13; cytarabine 20 mg/d, d 6-19; G-CSF 300 µg/d, d 6-19."( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015
)
0.63
"Decitabine combined with CAG regimen is effective and safe for treatment of MDS-RAEB and refractory AML patients, which can prolong lives of patiens with refractory hematological diseases."( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015
)
0.42
"The efficacy and safety of a modified CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen with an increased aclarubicin dosage [high-dose (HD)-CAG] were observed in 145 patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and compared to the results of 172 patients treated with a conventional CAG regimen."( Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y, 2015
)
1.04
"We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype."( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015
)
0.42
"From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis."( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015
)
0.42
"Decitabine alone or combination with AAG can improve outcome of AML/MDS with a complex karyotype, there being no significant difference decitabine in inducing remission rates in patients with different karyotype."( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015
)
0.42
"In this study we retrospectively analyzed 53 refractory or relapsed CN- AML patients receiving the therapy including decitabine combined with CAG and CAG- like regimen in our center from April 2011 to October 2014."( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015
)
0.42
"Decitabine combined with CAG or CAG-like regimen was an effective and safe treatment for refractory or relapsed CN- AML patients."( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015
)
0.42
"To observe the efficacy and safety of modified Shengma Biejia Decoction (MSBD) combined with CAG program in treating elderly acute myeloid leukemia (AML) patients with yin deficiency toxin stasis syndrome (YDTSS)."( [Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome].
Chen, JY; Dai, XB; Jiang, PJ; Ni, HW; Sun, XM; Zhang, WX, 2016
)
0.43
"MSBD combined with CAG program in treating elderly AML patients with YDTSS, with efficacy enhancing toxicity reducing effect, had distinct advantages in improving physical condition and clinical symptoms, and reducing transfusion dependency."( [Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome].
Chen, JY; Dai, XB; Jiang, PJ; Ni, HW; Sun, XM; Zhang, WX, 2016
)
0.43
"Homoharringtonine combined with aclarubicin and cytarabine (HAA) is a highly effective treatment for acute myeloid leukemia (AML), especially for t(8;21) AML."( Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
Cao, J; Chen, C; Chen, W; Ding, NN; Feng, H; Niu, MS; Qiu, TT; Wu, QY; Xu, KL; Zhu, HH, 2016
)
1
"To investigate the clinical efficacy of low-dose decitabine combined with CAG regimen in patients with myelodysplastic syndrome-refractory anemia with excess blasts (MDS-RAEB) through retrospective analysis."( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017
)
0.46
"Thirty-six patients with MDS-RAEB who ever received low-dose decitabine combined with CAG regimen were enrolled into decitabine + CAG group and 40 patients with MDS-RAEB treated by decitabine alone in our center were enolled into the control group."( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017
)
0.46
"Low-dose decitabine combined with CAG regimen has better clinical efficacy for patients with MDS-RAEB than that of decitabine alone."( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017
)
0.46
"We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy."( Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Hong, M; Huang, J; Li, J; Lian, Y; Qian, S; Wu, Y; Zhang, X; Zhao, H; Zhao, X; Zhu, Y, 2018
)
0.91
"Thalidomide in combination with chemotherapy is an alternative treatment option for elderly patients with AML."( Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.
Chen, C; Xu, W; Yang, J, 2018
)
0.48
"PubMed, EMbase, The Cochrane Library, WanFang Data and CNKI databases were searched to collect randomized controlled trials (RCTs) of decitabine combined with CAG regimen for intermediate or high risk MDS and AML from inception to March, 2018."( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Cao, YP; Li, JG; Zhang, JL, 2019
)
0.75
"To evaluate the efficacy of decitabine combined with low-dose CEG regimen (DCEG) and decitabine combined with low-dose CAG regimen (DCAG) in the treatment of elderly patients with MDS and MDS-transformed acute myeloid leukemia (AML)."( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020
)
0.56
" The treament results of decitabine combined with CEG and decitabine combined with CAG were compared."( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020
)
0.56
"Decitabine combined with CEG regimen could improve the survival of patients with high-risk MDS and MDS-transformed AML."( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020
)
0.56
" Furthermore, CCK-8 was used to determine the effects of HCA, alone or in combination with apoptosis inhibitors, necroptosis inhibitors, ferroptosis inhibitors, or autophagy inhibitors, on the proliferation of HL60 and THP1 cells and to screen for possible HCA-mediated death pathways in AML cells."( Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
Chen, P; Wang, D; Wang, F; Xie, M; Yang, M, 2022
)
0.98

Bioavailability

ExcerptReferenceRelevance
" Following oral administration aclarubicin was rapidly absorbed and its bioavailability amounted to 35 per cent."( [Pharmacokinetic study of aclarubicin. The pharmacokinetics of the preparation and its biologically active metabolites in the blood of rats].
Firsov, AA; Fomina, IP; Geodakian, SV, 1987
)
0.86

Dosage Studied

A new dosage formulation (ACR-CH) was developed for the treatment of lymph node metastases in patients with breast cancer. Aclarubicin(ACR) adsorbed on activated carbon particles (CH), was studied for adsorption and desorption onto and from CH.

ExcerptRelevanceReference
"A new dosage form (ACR-CH), a suspension of small activated carbon particles adsorbing aclarubicin, was studied for its toxicity and histopathological effects on organs in mice."( A new dosage form comprising a suspension of activated carbon particles adsorbing aclarubicin: toxicity in mice.
Hagiwara, A; Ito, M; Iwamoto, A; Matsumoto, S; Muranishi, S; Sasabe, T; Takahashi, T; Yoneyama, C, 1991
)
0.73
"A new dosage form (ACR-CH) comprising aclarubicin adsorbed on activated carbon particles was designed to sustain release of aclarubicin."( Selective distribution of aclarubicin to regional lymph nodes with a new dosage form: aclarubicin adsorbed on activated carbon particles.
Hagiwara, A; Iwamoto, A; Matsumoto, S; Muranishi, S; Takahashi, T; Yoneyama, C, 1991
)
0.85
"A new dosage form (ACR-CH), aclarubicin(ACR) adsorbed on activated carbon particles (CH), was studied for adsorption and desorption onto and from CH."( [Adsorption and desorption of aclarubicin into and from activated carbon particles as drug carrier--an in vitro study].
Hagiwara, A; Iwamoto, A; Matsumoto, S; Muranishi, S; Takahashi, T; Yoneyama, C; Yoshikawa, H, 1991
)
0.86
", the present cisplatin dosing schedule was highly effective as second-line therapy in these patients."( New cisplatin schedule in combination with aclarubicin (ACR) with high response rate in recurrent gynecological adenocarcinomas.
Chen, JT; Hasumi, K; Hirai, Y; Masubuchi, K; Shimizu, Y, 1990
)
0.54
"A new dosage form consisting of small activated carbon particles which adsorb Aclacinomycin A, Adriamycin, Mitomycin C or Pepleomycin was prepared in order to deliver larger amounts of anticancer agents to the lymph nodes through the high ability of lymphatics to adsorb particles."( Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases.
Ahn, T; Hagiwara, A; Iwamoto, A; Takahashi, T; Torii, T; Ueda, T,
)
0.13
" The schedule and dosage of the anthracycline antibiotic that produced the maximum prolongation of life had no effect on peripheral platelet levels or packed red cell volume."( WEHI-3B D+ Y1 leukemia cells as a model system to assess the induction of differentiation in vivo.
Carman, MD; Gamba-Vitalo, C; Sartorelli, AC, 1989
)
0.28
" Low dosage Ara-C has been used with great success in several clinical trials."( Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells.
Hassan, HT; Rees, JK, 1989
)
0.28
" Used in this dosage schedule, aclarubicin is an active, but toxic, agent in the acute myelogenous leukemias."( Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
Amare, M; Athens, JW; Beltran, G; Bull, FE; Coltman, CA; Dabich, L; Van Slyck, EJ; Weick, JK, 1986
)
0.87
"In a phase I-II trial, 38 patients with acute myeloid leukemia (AML) were given single drug induction therapy with aclarubicin (ACM) according to two dosing schedules: treatment 1: 10 to 30 mg/m2/d to a maximum total dose of 300 mg/m2 or until development of unacceptable toxicity: treatment 2: 15 mg/m2/d in ten-day courses separated by ten-day intervals."( [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Benavides, M; Delgado, M; Gastiaburu, J; Goldschmidt, E; Machover, D; Mathe, G; Misset, JL; Vandenbulcke, JM, 1987
)
0.79
" At that dosage level, aclacinomycin A also induced differentiation, while doxorubicin was ineffective, a finding consistent with the effects of these anthracyclines on HL-60 cells in suspension culture."( Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation.
Brown, BJ; Marsh, JC; Nierenburg, M; Sartorelli, AC; Schwartz, EL, 1983
)
0.27
" Colony-forming cells from mice, dogs, and humans were all found to have exponential dose-response curves for the agents studied, with variation of the slopes between species and agents."( Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity.
Brown, BJ; Marsh, JC; Nierenburg, MM, 1983
)
0.27
" The age-response with high concentrations of the drug reflected the differences in the size of the shoulder of the dose-response curve, while that with low drug concentrations reflected the presence or absence of the initial small decrease in survival."( Effect of aclacinomycin-A on survival and progression of mouse L cells through the cell cycle.
Miyamoto, T; Tanabe, M, 1983
)
0.27
"Aclacinomycin (ACM), a new anthracycline antibiotic compound, was given intravenously q x 3 to 6 weeks in a dosage of 4 x 60 mg/4 days to 10 patients with metastasizing breast cancer and 5 patients with gastric carcinoma."( [Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors].
Gössinger, H; Lenzhofer, R; Moser, K; Rainer, H; Schneeweiss, B, 1983
)
0.27
"Wistar rats, both male and female, were treated with aclacinomycin A at 4 dosage levels (0."( [Subacute toxicity of aclacinomycin A in rats (author's transl)].
Hirano, S; Hori, S; Iguchi, H; Ohmori, K; Sato, H; Shirai, M, 1980
)
0.26
"5 mg/kg showed R wave amplitude elevation during dosing period, and PR interval prolongation, R wave amplitude elevation and S wave amplitude reduction during recovery period."( [Cardiotoxic study of aclacinomycin A. Subacute cardiotoxicity of aclacinomycin A and its recovery in hamsters (author's transl)].
Hirano, S; Sunaga, T; Tone, H, 1980
)
0.26
"Male and female Wistar rats were treated with aclacinomycin A, a new anthracycline antitumor antibiotic, at 5 dosage levels (0."( [Chronic toxicity of aclacinomycin A in rats (author's transl)].
Hirano, S; Hori, S; Iguchi, H; Ohmori, K; Sato, H; Shirai, M, 1980
)
0.26
"A new dosage formulation (ACR-CH), composed of aclarubicin (ACR) bound to fine activated carbon particles, was developed for the treatment of lymph node metastases in patients with breast cancer."( [Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles].
Hagiwara, A; Imanishi, T; Ohgaki, M; Ohyama, T; Sakakibara, T; Sawai, K; Shimotsuma, M; Shirasu, M; Tsujimoto, H; Yamazaki, J, 1995
)
0.77
" From these results, it appears that the new dosage form of aclacinomycin A, ACR-CH, with superior therapeutic efficacy against lymph node metastases, can also enhance the immune response of regional lymph node cells."( Enhancement of various non-specific immune effector functions in mice by local injection of aclacinomycin A adsorbed onto activated carbon particles (ACR-CH).
Hagiwara, A; Itoh, M; Ozaki, K; Sakakura, C; Sasaki, S; Shobayashi, S; Takahashi, T; Tsujimoto, H; Yamane, T, 1993
)
0.29
" Pirarubicin and doxorubicin, but not aclarubicin, caused a parallel rightward shift of the dose-response curve for the negative inotropic effect of acetylcholine."( Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart.
Akera, T; Chugun, A; Hagane, K; Hirano, S; Kondo, H; Temma, K, 1993
)
0.8
"05) already at the lowest dosage tested (1 microgram/ml for 1 min)."( Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro.
Loeffler, KU; Schmidt, JF, 1996
)
0.29
"Echocardiographic reports on 144 adults receiving anthracycline therapy and 18 controls were reviewed for the possible relationship between dosage and ejection fractions."( [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
Horikawa, K; Okada, Y; Sano, M, 1997
)
0.3
"A new dosage formulation (ACR-CH), composed of aclarubicin (ACR) bound to fine activated carbon particles, has been developed for the treatment of lymph node metastases in breast cancer."( [Visualising lymph nodes by aclarubicin bound to activated carbon particles in breast cancer surgery].
Hagiwara, A; Imanishi, T; Ohgaki, M; Sakakura, C; Sawai, K; Shirasu, M; Takahashi, T; Togawa, T; Yamaguchi, T; Yamasaki, J, 1997
)
0.85
" However, with regard to reproliferation, long-term cultures (or long-term animal models, respectively) have to be used in further evaluating the appropriate dosage for this purpose."( Effect of aclacinomycin A on in vitro cultures of porcine lens epithelial cells.
Fluegel, B; Hansen, LL; Loeffler, KU; Meyer, JH; Schmidt, JF, 1998
)
0.3
" The mice were randomly divided into 5 groups of 6 each: ACM group (8 mg/kg bm); group of high dosage of MPNS-ACM (8 mg/kg bm); group of low dosage of MPNS-ACM (1."( Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor.
Deng, YH; Gao, H; Shen, XZ; Wang, JY; Zhang, W, 2004
)
0.32
" The inhibitory rates of ACM (8 mg/kg bm), high dosage of MPNS-ACM (8 mg/kg bm), low dosage of MPNS-ACM (1."( Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor.
Deng, YH; Gao, H; Shen, XZ; Wang, JY; Zhang, W, 2004
)
0.32
" Low-dose Ara-C was given subcutaneously at a dosage of 10 mg/m2 every 12 hours on days 1 to 14."( Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patien
Chen, FY; Hou, M; Jin, J; Li, JM; Liang, H; Qiu, XF; Qiu, ZC; Shen, Y; Shen, ZX; Song, EY; Song, YP; Wu, DP, 2005
)
1.77
" We investigated ID6105-induced apoptosis and in vivo efficacy on experimental tumors, and also defined its optimal dosing schedule."( Apoptosis induced by ID6105, a new anthracycline (11-hydroxyaclacinomycin X, Hyrubicin), and its anti-tumor effects on experimental tumor models.
Hong, SK; Hong, YS; Jeon, YJ; Kim, TY; Lee, HS; Lee, JJ; Ryu, JS, 2007
)
0.34
"The efficacy and safety of a modified CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen with an increased aclarubicin dosage [high-dose (HD)-CAG] were observed in 145 patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and compared to the results of 172 patients treated with a conventional CAG regimen."( Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y, 2015
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (8)

ClassDescription
anthracyclineAnthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
aminoglycoside
trisaccharide derivativeAn oligosaccharide derivative that is formally obtained from a trisaccharide.
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
tetracenequinones
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)9.90000.00001.284810.0000AID52347
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)1.10600.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.70400.00030.769310.0000AID625217
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (81)

Processvia Protein(s)Taxonomy
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID1692821Induction of relocalization of GFP-tagged Topo2a (unknown origin) expressed in human MEL-JUSO cells at 10 uM incubated for 15 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1692810Induction of DNA damage in human K562 cells assessed as induction of DNA break formation by measuring H2AX phosphorylation at 10 uM incubated for 2 hrs by Western blot analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID1692816Cytotoxicity in human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID1692818Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID52347Concentration inhibiting Clostridium histolyticum collagenase.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Inhibition of collagenase by aranciamycin and aranciamycin derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID101086Tested for the cytotoxicity (continuous incubation) against L1210 leukemia cells determined by clonogenic assay.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID101085Tested for the cytotoxicity(1 hour incubation) against L1210 leukemia cells.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID83957Tested for the cytotoxicity (continuous incubation) against human colon tumor cell lines (HT 29) determined by clonogenic assay.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID83956Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines (HT 29).1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID213356Inhibitory activity against trypsin at 10e-5 M; NI = no inhibition1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Inhibition of collagenase by aranciamycin and aranciamycin derivatives.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1692817Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1692813Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1692815Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID50757Tested for the cytotoxicity (continuous incubation) against human colon tumor cell lines (colon 4)determined by clonogenic assay.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID54463Tested for the binding affinity for DNA by intercalation between adjacent base pairs of the helix.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID220262Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Inhibition of collagenase by aranciamycin and aranciamycin derivatives.
AID21036Tested for the partition coefficient between water and n-octanol.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID50756Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines colon 4).1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationship of anthracyclines in vitro.
AID1692812Induction of histone eviction in human MEL-JUSO cells assessed as release of photoactivated green fluorescent protein-labeled histone H2A at 10 uM incubated for 2 hrs by time-lapse confocal microscopy2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1692814Cytotoxicity in human MEL-JUSO cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID67638Inhibitory activity against elastase at a concentration of 10e-5 M; NI means no inhibition1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Inhibition of collagenase by aranciamycin and aranciamycin derivatives.
AID361989Antitumor activity against mouse L1210 cells in ip dosed BDF1 mouse administered once daily for 10 days2008Journal of natural products, Sep, Volume: 71, Issue:9
Moromycins A and B, isolation and structure elucidation of C-glycosylangucycline-type antibiotics from Streptomyces sp. KY002.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID399076Activity of AknS in presence of AknT2005Journal of natural products, Nov, Volume: 68, Issue:11
Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1692811Induction of DNA damage in human K562 cells assessed as induction of DNA break formation by measuring H2AX phosphorylation at 10 uM incubated for 2 hrs by constant-field gel electroporation method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (792)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990361 (45.58)18.7374
1990's214 (27.02)18.2507
2000's107 (13.51)29.6817
2010's88 (11.11)24.3611
2020's22 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.96 (24.57)
Research Supply Index6.83 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index47.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials97 (11.74%)5.53%
Reviews40 (4.84%)6.00%
Case Studies78 (9.44%)4.05%
Observational1 (0.12%)0.25%
Other610 (73.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study [NCT05258799]130 participants (Anticipated)Interventional2022-01-21Recruiting
A Pilot Study of Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy (RVCL) [NCT02723448]Phase 14 participants (Actual)Interventional2016-12-05Completed
Efficacy and Safety of Cladribine in Combination With G-CSF, Low-dose Cytarabine and Aclarubicin in Patients With Refractory/Relapsed Acute Myeloid Leukemia: a Phase 2 Clinical Trial [NCT03181815]Phase 248 participants (Anticipated)Interventional2016-01-01Recruiting
Comparing the Efficacy and Safety of Venetoclax Combined With Decitabine/Azacitidine and Aclarubicin Versus Venetoclax Combined With Decitabine/Azacitidine in Treatment-Naive Elderly Patients With Acute Myeloid Leukemia [NCT05264883]Phase 3170 participants (Anticipated)Interventional2021-03-01Recruiting
Efficacy and Safety of Cladribine in Combination With G-CSF,Low-dose Cytarabine and Aclarubicin in Newly Diagnosed Unfit Patients With Acute Myeloid Leukemia [NCT04254640]Phase 234 participants (Anticipated)Interventional2021-03-01Not yet recruiting
A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Elderly Newly Diagnosed Acute Myeloid Leukemia Patients. [NCT04083911]Phase 350 participants (Anticipated)Interventional2019-04-01Recruiting
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients [NCT04168138]20 participants (Anticipated)Interventional2019-11-01Recruiting
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial [NCT05382390]Phase 3130 participants (Anticipated)Interventional2022-01-21Recruiting
A Multi-center Randomized Open-label Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of Acute Myeloid Leukemia Patients [NCT03045627]Phase 2120 participants (Anticipated)Interventional2017-01-31Recruiting
A Phase 3, Open-Label, Multicenter, Randomized Study of SKLB1028 Versus Salvage Chemotherapy in Patients With FLT3-mutated Acute Myeloid Leukemia Refractory to or Relapsed After First-line Treatment(ALIVE) [NCT04716114]Phase 3315 participants (Anticipated)Interventional2021-03-24Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]